Rheumatoid arthritis (RA) is a chronic autoimmune disease. In the clinical treatment of RA, the anti-rheumatoid drug sinomenine hydrochloride (SIN) was administered as tablets or injections. It has low oral bioavailability, dose-dependent adverse reactions, poor patient compliance with injections, and fails to resolve patients' early pain problems.
View Article and Find Full Text PDF